William Blair Issues Positive Forecast for Medpace Earnings

Medpace Holdings, Inc. (NASDAQ:MEDP) – Equities researchers at William Blair raised their Q4 2024 EPS estimates for shares of Medpace in a research report issued to clients and investors on Tuesday, October 22nd. William Blair analyst M. Smock now anticipates that the company will post earnings of $2.87 per share for the quarter, up from their previous estimate of $2.86. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Medpace’s current full-year earnings is $11.77 per share. William Blair also issued estimates for Medpace’s Q2 2025 earnings at $3.06 EPS.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The company had revenue of $533.32 million during the quarter, compared to analyst estimates of $540.99 million. During the same quarter in the prior year, the business earned $2.22 earnings per share. Medpace’s revenue was up 8.3% on a year-over-year basis.

Other analysts have also issued reports about the stock. Baird R W lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. UBS Group lowered shares of Medpace from a “buy” rating to a “neutral” rating and cut their price target for the stock from $420.00 to $350.00 in a report on Friday, September 27th. TD Cowen reduced their price target on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research report on Wednesday. Deutsche Bank Aktiengesellschaft lowered their price objective on Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a research report on Wednesday, July 24th. Finally, StockNews.com lowered Medpace from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $380.00.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $330.22 on Friday. The business has a fifty day moving average price of $351.45 and a 200 day moving average price of $381.28. Medpace has a 1-year low of $239.00 and a 1-year high of $459.77. The stock has a market capitalization of $10.24 billion, a P/E ratio of 28.92, a price-to-earnings-growth ratio of 1.74 and a beta of 1.35.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Diversify Wealth Management LLC lifted its holdings in shares of Medpace by 16.4% during the third quarter. Diversify Wealth Management LLC now owns 1,434 shares of the company’s stock worth $473,000 after purchasing an additional 202 shares during the period. Davidson Capital Management Inc. raised its position in Medpace by 8.1% during the 3rd quarter. Davidson Capital Management Inc. now owns 8,393 shares of the company’s stock worth $2,802,000 after buying an additional 629 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Medpace by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,963 shares of the company’s stock worth $1,990,000 after buying an additional 2,322 shares during the last quarter. Smith Group Asset Management LLC lifted its stake in Medpace by 2.4% during the 3rd quarter. Smith Group Asset Management LLC now owns 77,038 shares of the company’s stock valued at $25,715,000 after acquiring an additional 1,809 shares during the period. Finally, Semanteon Capital Management LP purchased a new stake in shares of Medpace in the 3rd quarter valued at $340,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.